Health Canada has approved Ozempic in an effort to help reduce the risk of kidney decline for patients living with Type 2 diabetes. The decision comes after an international clinical trial found the risk of deteriorating kidney function was 24 per cent lower in patients taking Ozempic compared to those taking a placebo injection. Katherine Ward has this story and more in Health Matters for Tuesday Aug. 19, 2025.Â
Health Matters
Health Matters: Health Canada approves Ozempic to help reduce kidney decline
More Videos
-
Health Matters: Canada has highest number of measles cases in North America
-
Health Matters: What to know about the summer COVID-19 variant ‘Stratus’
-
Health Matters: Unlicensed Mitolux UV sunlamps may pose health risks, Health Canada says
-
Health Matters: Parts of Eastern Canada expected to see heat relief
-
Health Matters: Heat wave continues in Eastern Canada
You are viewing an .
View Original Article